Literature DB >> 11926139

[Plasma concentration of leptin, neuropeptide Y and tumor necrosis factor alpha in patients with cancers, before and after radio- and chemotherapy].

A Kowalczuk1, A Wiecek, E Franek, F Kokot.   

Abstract

In patients with cancers progressive reduction of body mass is frequently recent. Pathogenesis of cachexia in patients with cancer is multifactorial. Such factors as cytokines, peptides relieved by tumor mass and different forms of treatment as radio or chemotherapy may play a major role in the pathogenesis of cachexia in patients with cancer. The aim of this study was to assess the relationship between body fat and lean mass and plasma leptin, NPY and TNF concentrations in patients with cancer of oral cavity and pharynx, cancer of larynx and non-Hodgkin lymphoma (NIL). 30 patients (10 with cancer of oral cavity and pharynx, 10 with cancer of larynx and 10 with non-Hodgkin lymphoma) were enrolled into this study. Mean age of all cancer patients was 50 +/- 2.9 years (from 18 to 76 years). The control group consisted of 29 healthy subjects with a means age 48 +/- 3.5 years (from 18 to 75 years), properly chosen according to the body weight, BMI, gender and age as above mentioned groups of patients with cancer. In control and study groups body fat and not-fat mass was assessed before and after treatment using the bioelectrical impedance method. Before oncological therapy patients with cancer did not differ from healthy subject with regard to body weight and body mass index. After treatment significant: decrease of body weight, body fat mass and BMI was observed. Serum leptin, NPY and TNF concentrations were analysed in healthy subjects and patients with cancer before and after treatment. Before oncological treatment significantly lower serum leptin concentration in comparison to leptinaemia in control group was found. In contrast to serum leptin, NPY serum concentration was similar in patients with cancer and in control subjects. Serum concentration of TNF was significantly higher in patients with cancer in comparison to subjects of control group. After oncological treatment, serum leptin and NPY concentration did not change significantly. In contrast, serum TNF concentration decreased significantly after oncological therapy. From the results obtained in this study we can conclude, that in patients with cancer secretion of leptin is decreased in relation to body fat mass. However, contribution of this hormone to pathogenesis of cancer induced anorexia seems not to proven. From the other side, the role of TNF in pathogenesis of disregulation of leptin secretion seems to be very likely. After chemo or radiotherapy, serum NPY concentration did not change significantly. After this oncological treatment the relationship between serum leptin concentration and body mass is no longer significant.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11926139

Source DB:  PubMed          Journal:  Pol Arch Med Wewn


  5 in total

1.  The prognostic role of inflammation and hormones in patients with metastatic cancer with cachexia.

Authors:  Cemil Bilir; Huseyin Engin; Murat Can; Yasemin Bakkal Temi; Derya Demirtas
Journal:  Med Oncol       Date:  2015-02-01       Impact factor: 3.064

Review 2.  Leptin and its receptor in hematologic malignancies.

Authors:  Tian-Jie Han; Xin Wang
Journal:  Int J Clin Exp Med       Date:  2015-11-15

3.  The immunohistochemical peptidergic expression of leptin is associated with recurrence of malignancy in laryngeal squamous cell carcinoma.

Authors:  S Gallina; F Sireci; F Lorusso; D V DI Benedetto; R Speciale; D Marchese; C Costantino; G Napoli; V Tessitore; D Cucco; A Leone; G Bonaventura; M L Uzzo; G F Spatola
Journal:  Acta Otorhinolaryngol Ital       Date:  2015-02       Impact factor: 2.124

4.  Serum Exosomal lncRNA AC007099.1 Regulates the Expression of Neuropeptide-Related FAP, as a Potential Biomarker for Hepatocarcinogenesis.

Authors:  Luqian Li; Fei Xiao; Guolian Liu; Yufeng Chen
Journal:  Dis Markers       Date:  2022-02-10       Impact factor: 3.434

Review 5.  Potential Biomarkers of Fat Loss as a Feature of Cancer Cachexia.

Authors:  Maryam Ebadi; Vera C Mazurak
Journal:  Mediators Inflamm       Date:  2015-10-05       Impact factor: 4.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.